Upsher-Smith Widens Ophthalmic Portfolio With Launch of Brimonidine Tartrate And Timolol Maleate Opthalmic Solution

The AB-rated generic version of the trademarked product Combigan, Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, was just released, according to Upsher-Smith Laboratories, LLC (Upsher-Smith). A collaborative cooperation between Upsher-Smith and RAFARM UK has resulted in the development and distribution of six ophthalmic and otic ANDA products, which led to the product launch in question. According to IQVIA, the market for brimonidine tartrate and timolol maleate ophthalmic solution had U.S. sales of about $392 million for the 12 months ending in February 2023.

A reputable pharmaceutical firm in the United States, Upsher-Smith Laboratories, LLC, is dedicated to producing top-notch medicines and achieving long-term success. Its mission is to improve the health and quality of life for patients. The business offers both name brands and generics to a broad range of consumers, always supported by its attentive level of service, solid industry connections, and commitment to continuous supply. A well-known European manufacturer with an international focus, RAFARM is an innovation-driven pharmaceutical firm that is rapidly expanding.

It invests 13% of its net revenue in R&D. We at RAFARM open new markets and increase our exports across the globe. We invest in high-tech platforms for the development and production of injectables and ophthalmics as well as continually improve our knowledge of complicated pharmaceutical goods. We implement cutting-edge technology in our state-of-the-art sterile manufacturing facility and build new production lines with robotic tools and advanced technologies.